All In Biotech

Drug Trial Radar · NCT07017179

This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight

A Phase IIa Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD6234, AZD9550, and AZD6234 in Combination With AZD9550 in Chinese Participants Living With Obesity/Overweight

Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

16

Actual

Start

May 20, 2025

Primary completion

Oct 23, 2026

Study completion Oct 23, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Jun 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to assess the safety and tolerability, PK characterisation, efficacy, and immunogenicity of the study intervention, and it allows assessment of the monotherapy or combination therapy of AZD6234 and AZD9550 in different sub-studies.

Conditions

  • Obesity/Overweight

Interventions

  • AZD6234Drug

    Participants will receive a subcutaneous injection weekly

  • PlaceboDrug

    Participants will receive a subcutaneous injection weekly.

  • AZD9550Drug

    Participants will receive a subcutaneous injection weekly

  • PloceboDrug

    Participants will receive a subcutaneous injection weekly

  • AZD6234 in combination with AZD9550Drug

    Participants will receive a subcutaneous injection weekly

  • PlaceboDrug

    Participants will receive a subcutaneous injection weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 1).Time frame: From baseline to Day 141
  2. Numbers of participant with Adverse Events (AEs) and Serious adverse events (SAEs) (sub-study 2).Time frame: From baseline to Day 225

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Jinan, China

  • Research Site

    Nanjing, China

  • Research Site

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.